Blood Science (Oct 2022)

BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia

  • Yanqing Zhang,
  • Hailiang Bi,
  • Ying Wang,
  • Long Chen,
  • Jiaqi Pan,
  • Ping Xu,
  • Wei Wang,
  • Shaobin Yang

DOI
https://doi.org/10.1097/BS9.0000000000000129
Journal volume & issue
Vol. 4, no. 4
pp. 199 – 204

Abstract

Read online

Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with JAK2 V617F- positive ET who subsequently acquired BCR–ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored JAK2 V617F and BCR-ABL and observed multiple gene mutations, including IDH2, IDH1, ASXL1, KRAS, and RUNX1. It is important to be aware of this potentially clone evolution in disease progression.